Nanjing IASO Biotechnology Co., Ltd.

IASO Bio is a commercial-stage biopharmaceutical company in the Advanced Therapy Medicinal Product (ATMP) sector. Founded in 2017, it specializes in developing cell therapies and biologics for hematological malignancies and autoimmune diseases, with fully integrated platforms spanning discovery, development, manufacturing, and commercialization. Its portfolio includes ten products and product candidates, anchored by Equecabtagene Autoleucel (eque-cel), a CAR-T therapy approved in China for relapsed or refractory multiple myeloma.

IASO Bio was founded in 2017. It is a commercial-stage biopharmaceutical company in the Advanced Therapy Medicinal Product (ATMP) sector, specializing in cell therapies and biologics for hematological malignancies and autoimmune diseases. The company has fully integrated platforms spanning discovery, development, manufacturing, and commercialization. Its portfolio includes ten products and product candidates, anchored by Equecabtagene Autoleucel (eque-cel), a CAR-T therapy approved in China for relapsed or refractory multiple myeloma in patients who have progressed after at least three prior lines of therapy. The company is also developing eque-cel for earlier lines of r/r MM treatment and for autoimmune diseases including myasthenia gravis, multiple sclerosis, and systemic lupus erythematosus/lupus nephritis. Beyond eque-cel, IASO Bio is developing nine additional therapeutic candidates, including three autologous CAR-T therapies and five in vivo CAR-T cell therapies.

One of the few commercial-stage biopharmaceutical companies in the ATMP sector bringing China's breakthrough innovations to the global market.

• Equecabtagene Autoleucel (eque-cel)

  CAR-T therapy approved in China for relapsed or refractory multiple myeloma in patients who have progressed after at least three prior lines of therapy; also being developed for earlier lines of r/r MM and autoimmune diseases including MG, MS, and SLE/LN.

• FUCASO® (equecabtagene autoleucel)

  Registration application accepted by Australia's TGA.

• IASO208

  CD20-targeted in vivo CAR-T therapy that received FDA IND clearance.

• 2022-01-11

  Sana, IASO Bio and Innovent announce BCMA CAR licensing agreement[5]Sana、驯鹿医疗与信达生物宣布BCMA CAR许可合作prnasia.com

  Reported: 2022-01-10

  Sana Biotechnology, IASO Bio and Innovent announced a strategic collaboration and non-exclusive license under which IASO Bio and Innovent granted Sana commercial rights to their clinically validated fully human BCMA CAR structure for specified in vivo gene therapy and ex vivo hypoimmune cell therapy product development. IASO Bio and Innovent are eligible for an upfront payment, development and regulatory milestones, and sales royalties.

1. 1IASO，IASO Bio，IASO Biotherapeutics，IASO Biopharma，CT103A， CAR-T， cell therapy，dual-targeted CAR-Tiasobio.com
2. 2Company Overview / ABOUT IASO / IASO，IASO Bio，IASO Biotherapeutics，IASO Biopharma，CT103A， CAR-T， cell therapy，dual-targeted CAR-Tiasobio.com
3. 3Technology Platforms / SCIENCE & PRODUCTS / IASO，IASO Bio，IASO Biotherapeutics，IASO Biopharma，CT103A， CAR-T， cell therapy，dual-targeted CAR-Tiasobio.com
4. 4Nanjing IASO Biotechnology Co., Ltd. (China)wikidata.org
5. 5Sana、驯鹿医疗与信达生物宣布BCMA CAR许可合作prnasia.com